Bristol-myers Squibb Compnay

Astrazeneca Ab

Alexandra A Nirschl

Lawrence G Hamann

James Clifford Sutton

Janak Singh

Xiaojun Zhang

Jack Z Gougoutas

Chiajen Lai

John D DiMarco

John Anthony Grosso

Prashant P Deshpande

Jeffrey T Bien

Yan Zou

Chenchi Wang

Srividya Ramakrishnan

Peter Riebel

Hildegard Lobinger

Philip Michael Sher

Wei Meng

Yingzhi Bi

Eldon Scott Priestley

Mark C Manfredi

William N Washburn

Tammy C Wang

Chongqing Sun

Gang Wu

Terry Stouch

Wllliam N Washburn

John D Dimarco

The present invention relates to physical crystal structures of a compound of the formula I: wherein R, R, R, Rand Rare as defined herein, especially pharmaceutical compositions containing structures of compound I or II, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.

Crystal structures of SGLT2 inhibitors and processes for preparing same

The present invention relates generally to novel 2-(aryloxy)acetamides of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables W, Y, Z, R, R, and Rare as defined herein. These compounds are selective inhibitors of the serine protease coagulation factor VIIa which can be used as medicaments.

2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants

Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure wherein

Sulfonylpyrrolidine modulators of androgen receptor function and method

The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia, wherein R, R, R, X, Y and n are defined herein.

Bicyclic modulators of androgen receptor function

The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it0 is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

Phenylglycinamide derivatives useful as anticoagulants

The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W, Y, Z, R, R, R, and Rare as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R, R, X, Y and Z are defined herein.

2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer. These novel compounds have the structure or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, R, R, X and Z are defined herein.

2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors

Growing community of inventors

Yardley, PA, United States of America

Alexandra A Nirschl